https://orcid.org/0000-0002-8836-1593
References
- Longo DL. Imatinib changed everything. N Engl J Med. 2017;376(10):982–983.
- Yilmaz M, Lahoti A, O'Brien S, et al. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015;121(21):3894–3904.
- Chen J, Chen JK, Harris RC. EGF receptor deletion in podocytes attenuates diabetic nephropathy. JASN. 2015;26(5):1115–1125.
- François H, Coppo P, Hayman JP, et al. Partial Fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. Am J Kid Dis. 2008;51(2):298–301.
- Foster RR. The importance of cellular VEGF bioactivity in the development of glomerular disease. Nephron Exp Nephrol. 2009;113(1):e8–e15.
- New LA, Martin CE, Scott RP, et al. Nephrin tyrosine phosphorylation is required to stabilize and restore podocyte foot process architecture. JASN. 2016;27(8):2422–2435.
- Jones N, Blasutig IM, Eremina V, et al. Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes. Nature. 2006;440(7085):818–823.
- Izzedine H, Mangier M, Ory V, et al. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kid Int. 2014;85(2):457–470.
- Zhang SY, Kamal M, Dahan K, et al. c-mip impairs podocyte proximal signaling and induces heavy proteinuria. Sci Signaling. 2010;3(122):ra39–ra39.